ClinicalTrials.gg

Hepatitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 344 studies for Hepatitis across more than 10 countries. 52 are recruiting or about to start. 102 of them are mainly about Hepatitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 12 narrower conditions too, such as Hepatitis C: 4,601 studies, 465 open.

Status

Completed
211
Status unknown
40
Recruiting
36
Terminated
20
Not yet recruiting
13
Active, not recruiting
13

Phase

Phase 2
85
Phase 3
56
Phase 1
35
Phase 4
29
Early Phase 1
1

Where

United States
144
France
40
United Kingdom
31
Canada
28
Germany
26
China
25

Who develops what

Add Hepatitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 8 companies, 6 with this as their studies’ main aim; 4 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Vir Biotechnology, Bausch Health Companies and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Hepatitis A VaccinesRecent, limited
Evidence
  • NCT07793227 · Sinovac Biotech Co., Ltd · Phase 3 · live · comparator · “Hepatitis A vaccine (inactivated, adsorbed)” · registered Aug 2026
—11 study
vedolizumabRecent, limited
Evidence
  • NCT07619898 · Therakos LLC · Phase 2 · live · comparator · “Vedolizumab” · registered May 2026
Takeda98% of its industry studiesUS: Takeda (FDA 2014)EU: Takeda (EMA 2014)11 study
InfliximabRecent, limited
Evidence
  • NCT07619898 · Therakos LLC · Phase 2 · live · comparator · “Infliximab” · registered May 2026
Johnson & Johnson38% of its industry studiesUS: Johnson & Johnson (FDA 1998) + 3 othersEU: Johnson & Johnson (EMA 1999) + 3 others11 study

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tobevibart☆ Track2 live phase-3 studies: NCT06903338, NCT07128550Vir Biotechnology, Inc.
elebsiran☆ Track2 live phase-3 studies: NCT06903338, NCT07128550Vir Biotechnology, Inc.
Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)☆ Track1 live phase-3 study: NCT07793227Sinovac Biotech Co., Ltd
larsucosterol☆ Track1 live phase-3 study: NCT07428538Bausch Health Companies Inc.

The 4 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.tobevibart, elebsiran · Vir Biotechnology, Inc. · Phase 2 main aimstudied with bulevirtideNCT07142811 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection — primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48 · 100 enrolled
  • Dec 2026 est.tobevibart, elebsiran · Vir Biotechnology, Inc. · Phase 3 main aimstudied with bulevirtideNCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide — primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24 · 150 enrolled
  • 11 May 2027 est.Hepatitis B Virus Antisense Oligonucleotide AHB-137 · AusperBio Therapeutics Inc. · Phase 2 named, not the main aimNCT07654283 Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions — primary endpoint: Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) · 70 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Reverse transcriptase inhibitors 8 · Integrase inhibitors 4

Coming up

15studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger. 6 (17%) take children under 18. 2 (6%) are for women only and 0 (0%) for men only; 8 (22%) take healthy volunteers.

Recruiting studies that take each age, of 36
AgeWomenMen
104 (11%)3 (8%)
1833 (92%)31 (86%)
3035 (97%)33 (92%)
4035 (97%)33 (92%)
5035 (97%)33 (92%)
6533 (92%)32 (89%)
7527 (75%)26 (72%)
8525 (69%)24 (67%)

Across all 344 studies, recruiting or not: 46% stop at 75 or younger and 31% at 65; 21% take children; 3% are for women only and 3% for men only; 27% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatitis studies take

Of 23 phase 3 interventional studies under Hepatitis, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 230 mo24–40 · 22 studies——
Phase 326 mo20–38 · 23 studies——
Interventional, no phase26 mo15–39 · 33 studies——
Observational59 mo37–195 · 36 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 344. Browse all 344 → or search them.